New vaccine aims to supercharge COVID-19 immunity
NCT ID NCT06810934
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing two experimental COVID-19 booster vaccines in 80 healthy volunteers aged 40-64. One vaccine includes an extra component called 's3' designed to improve the body's immune response. Participants will receive a single dose of either vaccine or a placebo and be monitored for side effects and immune responses. The goal is to see if these vaccines are safe and if the s3 component leads to broader, longer-lasting protection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ad35-vectored SARS-CoV-2 RBD (XBB.1.5) vaccine
What this could lead to
If successful, this could lead to a more effective COVID-19 booster that provides broader and longer-lasting protection against current and future variants.
What could go wrong
This is an early-phase trial with only 80 participants, so results may not apply to the general population. The vaccine may not produce stronger immunity than existing boosters, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCLA Westwood
RECRUITINGLos Angeles, California, 90095, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCSF Community and Clinical Research Center
RECRUITINGSan Francisco, California, 94110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact